<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01185353</url>
  </required_header>
  <id_info>
    <org_study_id>13854</org_study_id>
    <secondary_id>I4V-MC-JADA</secondary_id>
    <secondary_id>CTRI/2011/06/001834</secondary_id>
    <nct_id>NCT01185353</nct_id>
  </id_info>
  <brief_title>A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2b Study of LY3009104 in Patients With Active Rheumatoid Arthritis on Background Methotrexate Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the safety and efficacy of LY3009104 in participants
      with Rheumatoid Arthritis (RA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of the following:

        -  Screening period: 4 to 28-days

        -  Part A: a 12-week blinded, placebo controlled treatment period

        -  Part B: a 12-week blinded extension period

        -  Part C: an optional 52-week open-label extension period

        -  Part D: an additional optional 52-week open-label extension period

        -  Follow up period: 28 days
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) * 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 12 - Model Based Dose Response</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) * 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 24</measure>
    <time_frame>Baseline through Weeks 2, 4, 8, 12, 16, 20, 24</time_frame>
    <description>ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants treated) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an ACR20 Response Baseline Through Weeks 76 and 128</measure>
    <time_frame>Baseline through Weeks 76 and 128</time_frame>
    <description>ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an ACR 50 Responder Index Response Baseline Through Week 24</measure>
    <time_frame>Baseline through Weeks 2, 4, 8, 12, 16, 20, 24</time_frame>
    <description>ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an ACR50 Response Baseline Through Weeks 76 and 128</measure>
    <time_frame>Baseline through Weeks 76 and 128</time_frame>
    <description>ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an ACR70 Responder Index Response Baseline Through Week 24</measure>
    <time_frame>Baseline through Weeks 2, 4, 8, 12, 16, 20, 24</time_frame>
    <description>ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an ACR70 Response Baseline Through Weeks 76 and 128</measure>
    <time_frame>Baseline through Weeks 76 and 128</time_frame>
    <description>ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an ACR50 Response Baseline Through Week 12 - Model Based Dose Response</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) * 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR Percent Improvement (ACR-N)</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in RA that characterizes percentage (%) of improvement in disease activity from baseline based on ACR core set. This index was calculated as minimum of a) % of improvement in TJC, b) % of improvement in SJC, and c) third highest percentage of improvement of remaining 5 ACR core criteria: If ≥3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Percentage of improvement was truncated to a range of -100 to 100 to minimize impact of outliers (greater scores indicate greater % improvement) and negative scores indicate a decline. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Weeks 12 and 24 in Tender and Swollen Joint Counts (TJC and SJC)</measure>
    <time_frame>Baseline, Weeks 12 and 24</time_frame>
    <description>TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Weeks 76 and 128 in TJC and SJC</measure>
    <time_frame>Baseline, Weeks 76 and 128</time_frame>
    <description>TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Weeks 12 and 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score</measure>
    <time_frame>Baseline, Weeks 12 and 24</time_frame>
    <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Weeks 76 and 128 in HAQ-DI Score</measure>
    <time_frame>Baseline, Weeks 76 and 128</time_frame>
    <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Weeks 12 and 24 in High-Sensitivity C-Reactive Protein (hsCRP)</measure>
    <time_frame>Baseline, Weeks 12 and 24</time_frame>
    <description>hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Weeks 76 and 128 in hsCRP</measure>
    <time_frame>Baseline, Weeks 76 and 128</time_frame>
    <description>hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Weeks 12 and 24 in Erythrocyte Sedimentation Rate (ESR)</measure>
    <time_frame>Baseline, Weeks 12 and 24</time_frame>
    <description>ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Weeks 76 and 128 in ESR</measure>
    <time_frame>Baseline, Weeks 76 and 128</time_frame>
    <description>ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Weeks 12 and 24 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain</measure>
    <time_frame>Baseline, Weeks 12 and 24</time_frame>
    <description>Physician's and Patient's Assessments of Disease Activity (DA) assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeters (mm), where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis was also assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Weeks 76 and 128 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain</measure>
    <time_frame>Baseline, Weeks 76 and 128</time_frame>
    <description>Physician's and Patient's assessments of DA assessed using a VAS that ranged from 0 to 100 mm, where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Weeks 12 and 24 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)</measure>
    <time_frame>Baseline, Weeks 12 and 24</time_frame>
    <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, and remission was DAS28-CRP &lt;2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Weeks 76 and 128 in DAS28-CRP</measure>
    <time_frame>Baseline, Weeks 76 and 128</time_frame>
    <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using visual analog scale (VAS) (patient's global VAS). DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP &lt;2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders According to European League Against Rheumatism Responder Index Based on 28-joint Count (EULAR28) Baseline Through Weeks 12 and 24</measure>
    <time_frame>Baseline through Weeks 12 and 24</time_frame>
    <description>EULAR28 categorizes clinical response based upon improvement since baseline in DAS modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: TJC28, SJC28, CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score &gt;5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by &gt;0.6 units but ≤1.2 units or post-baseline DAS28 score &gt;3.2 with improvement by &gt;1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by &gt;1.2 units).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders According to EULAR28 Baseline Through Weeks 76 and 128</measure>
    <time_frame>Baseline, Weeks 76 and 128</time_frame>
    <description>EULAR28 categorizes clinical response based upon improvement since baseline in Disease Activity Score modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score &gt;5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by &gt;0.6 units but ≤1.2 units or post-baseline DAS28 score &gt;3.2 with improvement by &gt;1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by &gt;1.2 units).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 12 and 24</measure>
    <time_frame>Baseline through Weeks 12 and 24</time_frame>
    <description>Disease Activity Score (DAS) modified to include 28-joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP [milligrams per liter (mg/L)], and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores &lt;2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 76 and 128</measure>
    <time_frame>Baseline through Weeks 76 and 128</time_frame>
    <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores &lt;2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Through Week 12 in Duration (Minutes) of Morning Stiffness</measure>
    <time_frame>Baseline, Weeks 4, 8, 12</time_frame>
    <description>The Investigator asked participants about the duration of their morning stiffness (in minutes) in and around the joints and recorded the duration. The Investigator asked the participants about duration of morning stiffness on the day prior to the study visit to capture actual symptoms. If morning stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 12 in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains (physical functioning, bodily pain, role limitations due to physical problems and also emotional problems, general health, mental health, social functioning and vitality) and 2 component scores (PCS and MCS). The PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. The MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. Both PCS and MCS range from 0-100 with higher scores indicating better health or functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 12 in Brief Pain Inventory Modified Short Form (BPI-sf Modified) Worst-Pain-in-the Past-24-hours Item Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The BPI-sf modified is a self-administered questionnaire developed for the rapid assessment of pain. The BPI-sf modified provides information on the intensity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The questionnaire asks questions about pain relief, pain quality, and the participant's perception of the cause of pain. The BPI-sf modified uses a numeric rating scale from 0 (&quot;No pain&quot;) to 10 (&quot;Pain as bad as you can imagine&quot;). Since pain can be quite variable over a day, the BPI-sf modified asked participants to rate their pain at the time of responding to the questionnaire (right now), and also at its worst, least and average over the last 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 12 in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The FACIT-F Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 (&quot;Not at all&quot;) to 4 (&quot;Very much&quot;) for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104</measure>
    <time_frame>Baseline through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population PK: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104</measure>
    <time_frame>Baseline through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Through Week 12 in the ENSEMBLE Minimum Data Set 1.0</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">301</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>1 mg LY3009104 once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg LY3009104 once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mg LY3009104 once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 mg LY3009104 once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo once daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg LY3009104 twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Not utilized in Part A) After 12 weeks treatment with 1 mg LY3009104 once daily or Placebo once daily in Part A, administered orally twice daily for 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3009104</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>1 mg LY3009104 once daily</arm_group_label>
    <arm_group_label>2 mg LY3009104 once daily</arm_group_label>
    <arm_group_label>4 mg LY3009104 once daily</arm_group_label>
    <arm_group_label>8 mg LY3009104 once daily</arm_group_label>
    <arm_group_label>2 mg LY3009104 twice daily</arm_group_label>
    <other_name>Janus Kinase (JAK)1/JAK2 Inhibitor</other_name>
    <other_name>JAK1/2 Inhibitor</other_name>
    <other_name>INCB028050</other_name>
    <other_name>baricitinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Administered orally as background therapy</description>
    <arm_group_label>1 mg LY3009104 once daily</arm_group_label>
    <arm_group_label>2 mg LY3009104 once daily</arm_group_label>
    <arm_group_label>4 mg LY3009104 once daily</arm_group_label>
    <arm_group_label>8 mg LY3009104 once daily</arm_group_label>
    <arm_group_label>Placebo once daily</arm_group_label>
    <arm_group_label>2 mg LY3009104 twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have active RA

          -  Must regularly use methotrexate (MTX) for at least 12 weeks before your participation
             in this study

          -  Must have American College of Rheumatology (ACR) functional class I, II, or III

          -  Must have C-reactive protein (CRP) measurement &gt; 1.2 times upper limit of normal (ULN)
             or Erythrocyte Sedimentation Rate (ESR) &gt; ULN [28 millimeters/hour (mm/hr)]

          -  Have laboratory values that in the opinion of the investigator do not pose an
             unacceptable risk to the participants if study drug would be administered

          -  Must have venous access sufficient to allow blood sampling as per the protocol

          -  Must be reliable and willing to be available for the duration of the study and are
             willing to follow study procedures

          -  Must be able to read, understand, and give written informed consent approved by Lilly
             or its designee and the ethical review board (ERB) governing the site

          -  Male participants: agree to use 2 forms of highly effective methods of birth control
             with female partners of childbearing potential during the study

          -  If you are a woman and you could become pregnant during this study, you must talk to
             the study doctor about birth control. You are required to use 2 forms of highly
             effective methods of birth control to avoid getting pregnant during the study

          -  If you are a post-menopausal woman, you must be at least 45 years of age and have not
             menstruated for the last 12 months

          -  If you are a woman between 40 and 45 years of age, test negative for pregnancy, and
             have not menstruated during the last 12 months only, you must have an additional blood
             test

          -  For participants receiving corticosteroids, you must be on a dose not to exceed 10 mg
             of prednisone daily (or equivalent) and have been on the same dosing regimen for at
             least 6 weeks prior to randomization

          -  Continue to meet inclusion criteria for Parts A and B as applicable

          -  Part D only: have completed the 52 weeks (Week 24 to Week 76) of participation in Part
             C of the study without permanent study drug discontinuation and have not completed the
             Follow-Up Visit (approximately 28 days after the last dose of study drug)

        Exclusion Criteria:

          -  Must not have received any parenteral corticosteroid administered by intra-articular,
             intramuscular (IM), or intravenous (IV) injection within 6 weeks prior to baseline

          -  Must not be concomitantly using non-steroidal anti-inflammatory drugs (NSAIDS), unless
             you are on a stable dose within the last 4 weeks

          -  Must not have received any prior biologic disease modifying anti-rheumatic drug
             (DMARD) therapy [such as Tumor necrosis factor-alpha (TNFα), interleukin (IL)-1, IL-6,
             T-cell or B-cell target therapies)

          -  Must not have used DMARDs other than methotrexate (MTX), hydroxychloroquine, or
             sulfasalazine within the last 8 weeks

          -  Must not have used leflunomide within the last 12 weeks and have not received
             cholestyramine to speed up the elimination of leflunomide from your body

          -  Must not have previously been randomized, completed or withdrawn from this study or
             any other study investigating LY3009104

          -  Must not have received prior treatment with an oral JAK inhibitor

          -  Must not have a current or recent (within the last 30 days) viral, bacterial, fungal,
             or parasitic infection

          -  Must not have had a serious infection (for example, pneumonia, cellulitis, or bone or
             joint infections) or atypical mycobacterial infection within the last 6 months

          -  Must not have had symptomatic herpes zoster or herpes simplex infection within the
             last 90 days or have a history of disseminated/complicated herpes zoster

          -  Must not have evidence of human immunodeficiency virus (HIV) and/or positive human HIV
             antibodies

          -  Must not have evidence of hepatitis C virus (HCV) or active hepatitis B

          -  Must not have evidence or suspicion of active or latent tuberculosis (TB)

          -  Must not have another serious disorder or illness

          -  Must not be exposed to a live vaccine within the last 12 weeks

          -  Must not have donated more than 500 milliliters (mL) of blood within the last month

          -  Must not have had surgery on a joint that is to be assessed in the study within the
             last 2 months, or will require such during the study

          -  Must not be currently enrolled in, or discontinued within the last 30 days from a
             clinical trial involving an investigational drug or device or off-label use of a drug,
             or concurrently enrolled in any other type of medical research judged not to be
             scientifically or medically compatible with this study

          -  Presence of significant uncontrolled cerebro-cardiovascular [for example (eg),
             myocardial infarction (MI), unstable angina (UA), unstable arterial hypertension,
             severe heart failure or cerebrovascular accident], respiratory, hepatic, renal,
             gastrointestinal (GI), endocrine, hematologic or neuropsychiatric disorders, or
             abnormal laboratory values that in the opinion of the investigator pose an
             unacceptable risk to the participant if study drug would be administered
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paradise Valley</city>
        <state>Arizona</state>
        <zip>85253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ceska Lipa</city>
        <zip>470 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hlucin</city>
        <zip>748-01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hostivice</city>
        <zip>253-01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hustopece</city>
        <zip>693 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Prague</city>
        <zip>128 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ahmedabad</city>
        <zip>532004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyderabaad</city>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pune</city>
        <zip>411007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Trivandrum</city>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cuauhtemoc</city>
        <zip>06090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guadalajara</city>
        <zip>44158</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leon</city>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Czestochowa</city>
        <zip>42-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Krakow</city>
        <zip>30-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poznan</city>
        <zip>60-773</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bacau</city>
        <zip>600114</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>10584</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Galati</city>
        <zip>800587</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Iasi</city>
        <zip>700656</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kiev</city>
        <zip>03151</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyiv</city>
        <zip>01601</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Simferopol</city>
        <zip>95017</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ternopil</city>
        <zip>46002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Czech Republic</country>
    <country>Peru</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2010</study_first_posted>
  <results_first_submitted>March 10, 2017</results_first_submitted>
  <results_first_submitted_qc>March 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2017</results_first_posted>
  <disposition_first_submitted>February 10, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>February 10, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 14, 2012</disposition_first_posted>
  <last_update_submitted>May 22, 2017</last_update_submitted>
  <last_update_submitted_qc>May 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>RA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study consisted of 4 parts and a follow-up up to 28 days post the last dose of study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Milligrams (mg) LY3009104 QD - Part A</title>
          <description>Administered orally once daily (QD) for 12 weeks in Part A.
Methotrexate (MTX) was administered orally as background therapy.</description>
        </group>
        <group group_id="P2">
          <title>2 mg LY3009104 QD - Parts A and B</title>
          <description>Administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="P3">
          <title>4 mg LY3009104 QD - Parts A and B</title>
          <description>Administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="P4">
          <title>8 mg LY3009104 QD - Parts A and B</title>
          <description>Administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="P5">
          <title>Placebo QD - Part A</title>
          <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="P6">
          <title>2 mg LY3009104 BID - Part B</title>
          <description>Participants who received Placebo or 1 mg LY3009104 in Part A were re-randomized at Week 12 to receive 2 mg LY3009104 twice daily (BID) in Part B.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="P7">
          <title>4 mg LY3009104 QD - Part B</title>
          <description>Participants who received Placebo or 1 mg LY3009104 in Part A were re-randomized at Week 12 to receive 4 mg LY3009104 QD in Part B.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="P8">
          <title>4 mg LY3009104 QD - Parts C and D</title>
          <description>Participants who received 2 mg LY3009104 QD or BID in Part B were re-assigned at Week 24 to 4 mg LY3009104 QD in Part C.
Participants who received 4 mg LY3009104 QD in Part B continued to receive 4 mg LY3009104 QD in Part C.
Participants who completed Part C continued to receive 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="P9">
          <title>4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
          <description>Participants who received 2 mg LY3009104 QD or BID in Part B were re-assigned at Week 24 to 4 mg LY3009104 QD in Part C.
Participants who received 4 mg LY3009104 QD in Part B continued to receive 4 mg LY3009104 QD in Part C.
At Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.
Dose escalation criteria: ≥ 6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.
Participants who completed Part C received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="P10">
          <title>8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
          <description>Participants who received 8 mg LY3009104 QD in Part B remained on 8 mg LY3009104 QD in Part C.
Participants who completed Part C received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A (Weeks 0 Through 12)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="98"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="98"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="82"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B (Weeks 12 Through 24)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="63"/>
                <participants group_id="P7" count="63"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="59"/>
                <participants group_id="P7" count="57"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part C (Weeks 24 Through 76)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="108"/>
                <participants group_id="P9" count="61"/>
                <participants group_id="P10" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="92"/>
                <participants group_id="P9" count="53"/>
                <participants group_id="P10" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="16"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason missing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part D (Weeks 76 Through 128)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="79"/>
                <participants group_id="P9" count="47"/>
                <participants group_id="P10" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="76"/>
                <participants group_id="P9" count="40"/>
                <participants group_id="P10" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>1 mg LY3009104</title>
          <description>Administered orally QD for initial 12 weeks (Part A) followed by randomization to either 4 mg QD or 2 mg BID for an additional 12 weeks (Part B). After 24 weeks of treatment, participants were eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally QD for 52 weeks. After 76 weeks of treatment, participants were eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally QD for 52 additional weeks.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="B2">
          <title>2 mg LY3009104</title>
          <description>Administered orally QD for 24 weeks (Parts A and B). After 24 weeks of treatment, participants were eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally QD for 52 weeks. After 76 weeks of treatment, participants were eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally QD for 52 additional weeks.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="B3">
          <title>4 mg LY3009104</title>
          <description>Administered orally QD for 24 weeks (Parts A and B). After 24 weeks of treatment, participants were eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally QD for 52 weeks. After 76 weeks of treatment, participants were eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally QD for 52 additional weeks.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="B4">
          <title>8 mg LY3009104</title>
          <description>Administered orally QD for 24 weeks (Parts A and B). After 24 weeks of treatment, participants were eligible to participate in an open-label extension period (Part C). Part C: 8 mg administered orally QD for 52 weeks. After 76 weeks of treatment, participants were eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally QD for 52 additional weeks.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo administered orally QD for initial 12 weeks (Part A) followed by randomization to either 4 mg QD or 2 mg BID for an additional 12 weeks (Part B). After 24 weeks of treatment, participants were eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally QD for 52 weeks. After 76 weeks of treatment participants were eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally QD for 52 additional weeks.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="50"/>
            <count group_id="B5" value="98"/>
            <count group_id="B6" value="301"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.1" spread="11.07"/>
                    <measurement group_id="B2" value="50.7" spread="13.12"/>
                    <measurement group_id="B3" value="52.5" spread="10.42"/>
                    <measurement group_id="B4" value="52.7" spread="10.91"/>
                    <measurement group_id="B5" value="49.2" spread="12.15"/>
                    <measurement group_id="B6" value="51.2" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="85"/>
                    <measurement group_id="B6" value="249"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="78"/>
                    <measurement group_id="B6" value="227"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="70"/>
                    <measurement group_id="B6" value="224"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Rheumatoid Arthritis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.45" spread="3.885"/>
                    <measurement group_id="B2" value="5.53" spread="4.377"/>
                    <measurement group_id="B3" value="5.28" spread="4.466"/>
                    <measurement group_id="B4" value="6.63" spread="5.048"/>
                    <measurement group_id="B5" value="5.40" spread="4.283"/>
                    <measurement group_id="B6" value="5.62" spread="4.401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tender Joint Counts (TJC)</title>
          <description>TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy.</description>
          <units>number of joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.4" spread="10.90"/>
                    <measurement group_id="B2" value="23.0" spread="12.60"/>
                    <measurement group_id="B3" value="19.9" spread="12.71"/>
                    <measurement group_id="B4" value="24.4" spread="13.76"/>
                    <measurement group_id="B5" value="22.2" spread="12.06"/>
                    <measurement group_id="B6" value="22.2" spread="12.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen Joint Counts (SJC)</title>
          <description>SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.</description>
          <units>number of joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.2" spread="6.55"/>
                    <measurement group_id="B2" value="17.0" spread="9.32"/>
                    <measurement group_id="B3" value="14.8" spread="7.54"/>
                    <measurement group_id="B4" value="16.1" spread="7.92"/>
                    <measurement group_id="B5" value="15.8" spread="8.64"/>
                    <measurement group_id="B6" value="15.8" spread="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High Sensitivity C-Reactive Protein (hsCRP)</title>
          <description>HsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable hsCRP data at baseline.</population>
          <units>milligrams/liter (mg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="97"/>
                    <count group_id="B6" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.22" spread="12.410"/>
                    <measurement group_id="B2" value="12.02" spread="22.111"/>
                    <measurement group_id="B3" value="11.39" spread="16.941"/>
                    <measurement group_id="B4" value="14.32" spread="15.602"/>
                    <measurement group_id="B5" value="14.03" spread="23.527"/>
                    <measurement group_id="B6" value="12.81" spread="19.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythrocyte Sedimentation Rate (ESR)</title>
          <description>ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.</description>
          <units>millimeters/hour (mm/hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="98"/>
                    <count group_id="B6" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.2" spread="17.57"/>
                    <measurement group_id="B2" value="36.5" spread="14.62"/>
                    <measurement group_id="B3" value="35.4" spread="17.16"/>
                    <measurement group_id="B4" value="43.3" spread="18.17"/>
                    <measurement group_id="B5" value="39.9" spread="20.94"/>
                    <measurement group_id="B6" value="38.8" spread="18.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12</title>
        <description>ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) * 100.</description>
        <time_frame>Baseline through Week 12</time_frame>
        <population>All randomized participants who received placebo, 4 mg or 8 mg LY3009104 in Part A. Participants who had missing components of the ACR20 index at Week 12 had these components imputed by last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>4 or 8 mg LY3009104</title>
            <description>4 or 8 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12</title>
          <description>ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) * 100.</description>
          <population>All randomized participants who received placebo, 4 mg or 8 mg LY3009104 in Part A. Participants who had missing components of the ACR20 index at Week 12 had these components imputed by last observation carried forward (LOCF).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A priori p-value significance threshold: 1-sided ≤0.10</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 12 - Model Based Dose Response</title>
        <description>ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) * 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.</description>
        <time_frame>Baseline through Week 12</time_frame>
        <population>All randomized participants who received study drug in Part A. Participants who had missing components of the ACR20 index at Week 12 had these components imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 12 - Model Based Dose Response</title>
          <description>ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) * 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.</description>
          <population>All randomized participants who received study drug in Part A. Participants who had missing components of the ACR20 index at Week 12 had these components imputed by LOCF.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.6" lower_limit="42.2" upper_limit="67.1"/>
                    <measurement group_id="O2" value="55.2" lower_limit="42.3" upper_limit="67.6"/>
                    <measurement group_id="O3" value="74.3" lower_limit="63.1" upper_limit="84.1"/>
                    <measurement group_id="O4" value="77.2" lower_limit="65.9" upper_limit="86.7"/>
                    <measurement group_id="O5" value="42.1" lower_limit="32.9" upper_limit="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 24</title>
        <description>ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants treated) * 100.</description>
        <time_frame>Baseline through Weeks 2, 4, 8, 12, 16, 20, 24</time_frame>
        <population>All randomized participants who received study drug in Parts A and B. Participants who had missing components of the ACR20 index at analysis time points had these components imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 24</title>
          <description>ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants treated) * 100.</description>
          <population>All randomized participants who received study drug in Parts A and B. Participants who had missing components of the ACR20 index at analysis time points had these components imputed by LOCF.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="72"/>
                    <measurement group_id="O5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.</measurement>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.</measurement>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.</measurement>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="72"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.045</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.088</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an ACR20 Response Baseline Through Weeks 76 and 128</title>
        <description>ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) * 100.</description>
        <time_frame>Baseline through Weeks 76 and 128</time_frame>
        <population>All participants who received study drug in Parts C and D. Participants who had missing components of the ACR20 index at analysis time points had these components imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg LY3009104 QD - Parts C and D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C. During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.
Dose escalation criteria: ≥6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received 8 mg LY3009104 QD in Parts A, B and C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an ACR20 Response Baseline Through Weeks 76 and 128</title>
          <description>ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) * 100.</description>
          <population>All participants who received study drug in Parts C and D. Participants who had missing components of the ACR20 index at analysis time points had these components imputed by LOCF.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 76 (n=108, 61, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an ACR 50 Responder Index Response Baseline Through Week 24</title>
        <description>ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) * 100.</description>
        <time_frame>Baseline through Weeks 2, 4, 8, 12, 16, 20, 24</time_frame>
        <population>All randomized participants who received study drug in Parts A and B. Participants who had missing components of the ACR50 index at analysis time points had these components imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an ACR 50 Responder Index Response Baseline Through Week 24</title>
          <description>ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) * 100.</description>
          <population>All randomized participants who received study drug in Parts A and B. Participants who had missing components of the ACR50 index at analysis time points had these components imputed by LOCF.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.</measurement>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.</measurement>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.</measurement>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.162</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an ACR50 Response Baseline Through Weeks 76 and 128</title>
        <description>ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) * 100.</description>
        <time_frame>Baseline through Weeks 76 and 128</time_frame>
        <population>All participants who received study drug in Parts C and D. Participants who had missing components of the ACR50 index at analysis time points had these components imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg LY3009104 QD - Parts C and D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C. During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.
Dose escalation criteria: ≥6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received 8 mg LY3009104 QD in Parts A, B and C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an ACR50 Response Baseline Through Weeks 76 and 128</title>
          <description>ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) * 100.</description>
          <population>All participants who received study drug in Parts C and D. Participants who had missing components of the ACR50 index at analysis time points had these components imputed by LOCF.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 76 (n=108, 61, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an ACR70 Responder Index Response Baseline Through Week 24</title>
        <description>ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) * 100.</description>
        <time_frame>Baseline through Weeks 2, 4, 8, 12, 16, 20, 24</time_frame>
        <population>All randomized participants who received study drug in Parts A and B. Participants who had missing components of the ACR70 index at analysis time points had these components imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an ACR70 Responder Index Response Baseline Through Week 24</title>
          <description>ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) * 100.</description>
          <population>All randomized participants who received study drug in Parts A and B. Participants who had missing components of the ACR70 index at analysis time points had these components imputed by LOCF.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.</measurement>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.</measurement>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.</measurement>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.109</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an ACR70 Response Baseline Through Weeks 76 and 128</title>
        <description>ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) * 100.</description>
        <time_frame>Baseline through Weeks 76 and 128</time_frame>
        <population>All participants who received study drug in Parts C and D. Participants who had missing components of the ACR70 index at analysis time points had these components imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg LY3009104 QD - Parts C and D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C. During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.
Dose escalation criteria: ≥6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received 8 mg LY3009104 QD in Parts A, B and C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an ACR70 Response Baseline Through Weeks 76 and 128</title>
          <description>ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) * 100.</description>
          <population>All participants who received study drug in Parts C and D. Participants who had missing components of the ACR70 index at analysis time points had these components imputed by LOCF.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 76 (n=108, 61, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an ACR50 Response Baseline Through Week 12 - Model Based Dose Response</title>
        <description>ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) * 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.</description>
        <time_frame>Baseline through Week 12</time_frame>
        <population>All randomized participants who received study drug in Part A. Participants who had missing components of the ACR50 index at analysis time point had these components imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an ACR50 Response Baseline Through Week 12 - Model Based Dose Response</title>
          <description>ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant’s physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) * 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.</description>
          <population>All randomized participants who received study drug in Part A. Participants who had missing components of the ACR50 index at analysis time point had these components imputed by LOCF.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" lower_limit="16.0" upper_limit="39.2"/>
                    <measurement group_id="O2" value="18.8" lower_limit="9.9" upper_limit="29.7"/>
                    <measurement group_id="O3" value="34.4" lower_limit="23.1" upper_limit="46.7"/>
                    <measurement group_id="O4" value="39.2" lower_limit="27.1" upper_limit="52.2"/>
                    <measurement group_id="O5" value="12.0" lower_limit="6.5" upper_limit="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR Percent Improvement (ACR-N)</title>
        <description>ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in RA that characterizes percentage (%) of improvement in disease activity from baseline based on ACR core set. This index was calculated as minimum of a) % of improvement in TJC, b) % of improvement in SJC, and c) third highest percentage of improvement of remaining 5 ACR core criteria: If ≥3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Percentage of improvement was truncated to a range of -100 to 100 to minimize impact of outliers (greater scores indicate greater % improvement) and negative scores indicate a decline. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.</description>
        <time_frame>Baseline through Week 12</time_frame>
        <population>All randomized participants who received study drug in Part A. Participants who had missing components of the ACR-N at Week 12 had these components imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR Percent Improvement (ACR-N)</title>
          <description>ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in RA that characterizes percentage (%) of improvement in disease activity from baseline based on ACR core set. This index was calculated as minimum of a) % of improvement in TJC, b) % of improvement in SJC, and c) third highest percentage of improvement of remaining 5 ACR core criteria: If ≥3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Percentage of improvement was truncated to a range of -100 to 100 to minimize impact of outliers (greater scores indicate greater % improvement) and negative scores indicate a decline. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.</description>
          <population>All randomized participants who received study drug in Part A. Participants who had missing components of the ACR-N at Week 12 had these components imputed by LOCF.</population>
          <units>percentage of improvement</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.30" lower_limit="7.57" upper_limit="28.22"/>
                    <measurement group_id="O2" value="19.42" lower_limit="8.74" upper_limit="29.25"/>
                    <measurement group_id="O3" value="28.59" lower_limit="17.67" upper_limit="40.83"/>
                    <measurement group_id="O4" value="29.00" lower_limit="17.67" upper_limit="41.47"/>
                    <measurement group_id="O5" value="10.97" lower_limit="-0.39" upper_limit="21.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Weeks 12 and 24 in Tender and Swollen Joint Counts (TJC and SJC)</title>
        <description>TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.</description>
        <time_frame>Baseline, Weeks 12 and 24</time_frame>
        <population>All randomized participants who received study drug in Parts A and B and had TJC and SJC evaluated at analysis time points. LOCF was used to impute missing post-baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Weeks 12 and 24 in Tender and Swollen Joint Counts (TJC and SJC)</title>
          <description>TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.</description>
          <population>All randomized participants who received study drug in Parts A and B and had TJC and SJC evaluated at analysis time points. LOCF was used to impute missing post-baseline values</population>
          <units>number of joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TJC - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="12.70"/>
                    <measurement group_id="O2" value="-11.3" spread="13.50"/>
                    <measurement group_id="O3" value="-12.2" spread="10.45"/>
                    <measurement group_id="O4" value="-14.7" spread="12.97"/>
                    <measurement group_id="O5" value="-7.6" spread="12.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TJC - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore mean and standard deviation (SD) were not calculated.</measurement>
                    <measurement group_id="O2" value="-12.4" spread="12.60"/>
                    <measurement group_id="O3" value="-14.0" spread="9.54"/>
                    <measurement group_id="O4" value="-17.5" spread="11.23"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore mean and SD were not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SJC - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="7.24"/>
                    <measurement group_id="O2" value="-8.9" spread="9.03"/>
                    <measurement group_id="O3" value="-9.6" spread="6.49"/>
                    <measurement group_id="O4" value="-10.4" spread="8.88"/>
                    <measurement group_id="O5" value="-6.7" spread="7.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SJC - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore mean and SD were not calculated.</measurement>
                    <measurement group_id="O2" value="-10.0" spread="8.16"/>
                    <measurement group_id="O3" value="-10.5" spread="6.42"/>
                    <measurement group_id="O4" value="-12.2" spread="7.29"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore mean and SD were not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.480</p_value>
            <p_value_desc>P-value is for TJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <p_value_desc>P-value is for TJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for TJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P-value is for TJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.116</p_value>
            <p_value_desc>P-value is for SJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.201</p_value>
            <p_value_desc>P-value is for SJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for SJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value is for SJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Weeks 76 and 128 in TJC and SJC</title>
        <description>TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.</description>
        <time_frame>Baseline, Weeks 76 and 128</time_frame>
        <population>All participants who received study drug in Parts C and D and had TJC and SJC evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg LY3009104 QD - Parts C and D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C. During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.
Dose escalation criteria: ≥6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received 8 mg LY3009104 QD in Parts A, B and C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Weeks 76 and 128 in TJC and SJC</title>
          <description>TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.</description>
          <population>All participants who received study drug in Parts C and D and had TJC and SJC evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TJC - Week 76 (n=108, 61, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.7" spread="11.26"/>
                    <measurement group_id="O2" value="-16.0" spread="13.37"/>
                    <measurement group_id="O3" value="-18.1" spread="12.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TJC - Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.4" spread="11.01"/>
                    <measurement group_id="O2" value="-15.3" spread="12.56"/>
                    <measurement group_id="O3" value="-14.0" spread="13.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SJC - Week 76 (n=108, 61, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.6" spread="6.40"/>
                    <measurement group_id="O2" value="-12.9" spread="7.80"/>
                    <measurement group_id="O3" value="-12.4" spread="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SJC - Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4" spread="6.81"/>
                    <measurement group_id="O2" value="-12.4" spread="8.01"/>
                    <measurement group_id="O3" value="-11.6" spread="6.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Weeks 12 and 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score</title>
        <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.</description>
        <time_frame>Baseline, Weeks 12 and 24</time_frame>
        <population>All randomized participants who received study drug in Parts A and B and had HAQ-DI evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Weeks 12 and 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score</title>
          <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.</description>
          <population>All randomized participants who received study drug in Parts A and B and had HAQ-DI evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.528"/>
                    <measurement group_id="O2" value="-0.18" spread="0.524"/>
                    <measurement group_id="O3" value="-0.33" spread="0.459"/>
                    <measurement group_id="O4" value="-0.39" spread="0.497"/>
                    <measurement group_id="O5" value="-0.10" spread="0.406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore mean and SD were not calculated.</measurement>
                    <measurement group_id="O2" value="-0.18" spread="0.505"/>
                    <measurement group_id="O3" value="-0.32" spread="0.506"/>
                    <measurement group_id="O4" value="-0.44" spread="0.529"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore mean and SD were not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.167</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Weeks 76 and 128 in HAQ-DI Score</title>
        <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.</description>
        <time_frame>Baseline, Weeks 76 and 128</time_frame>
        <population>All participants who received study drug in Parts C and D and had HAQ-DI evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg LY3009104 QD - Parts C and D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C. During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.
Dose escalation criteria: ≥6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received 8 mg LY3009104 QD in Parts A, B and C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Weeks 76 and 128 in HAQ-DI Score</title>
          <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.</description>
          <population>All participants who received study drug in Parts C and D and had HAQ-DI evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 76 (n=108, 61, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.58"/>
                    <measurement group_id="O2" value="-0.29" spread="0.53"/>
                    <measurement group_id="O3" value="-0.55" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.61"/>
                    <measurement group_id="O2" value="-0.22" spread="0.56"/>
                    <measurement group_id="O3" value="-0.30" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Weeks 12 and 24 in High-Sensitivity C-Reactive Protein (hsCRP)</title>
        <description>hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.</description>
        <time_frame>Baseline, Weeks 12 and 24</time_frame>
        <population>All randomized participants who received study drug in Parts A and B and had hsCRP evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Weeks 12 and 24 in High-Sensitivity C-Reactive Protein (hsCRP)</title>
          <description>hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.</description>
          <population>All randomized participants who received study drug in Parts A and B and had hsCRP evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.14" spread="10.236"/>
                    <measurement group_id="O2" value="-3.39" spread="19.409"/>
                    <measurement group_id="O3" value="-7.06" spread="16.945"/>
                    <measurement group_id="O4" value="-2.32" spread="32.582"/>
                    <measurement group_id="O5" value="1.50" spread="34.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore mean and SD were not calculated.</measurement>
                    <measurement group_id="O2" value="-4.76" spread="18.695"/>
                    <measurement group_id="O3" value="-4.95" spread="19.819"/>
                    <measurement group_id="O4" value="-7.61" spread="17.548"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore mean and SD were not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.108</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.368</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Weeks 76 and 128 in hsCRP</title>
        <description>hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.</description>
        <time_frame>Baseline, Weeks 76 and 128</time_frame>
        <population>All participants who received study drug in Parts C and D and had hsCRP evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg LY3009104 QD - Parts C and D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C. During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.
Dose escalation criteria: ≥6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received 8 mg LY3009104 QD in Parts A, B and C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Weeks 76 and 128 in hsCRP</title>
          <description>hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.</description>
          <population>All participants who received study drug in Parts C and D and had hsCRP evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 76 (n=108, 61, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="22.43"/>
                    <measurement group_id="O2" value="-3.3" spread="14.28"/>
                    <measurement group_id="O3" value="-2.9" spread="25.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="13.66"/>
                    <measurement group_id="O2" value="-2.9" spread="21.88"/>
                    <measurement group_id="O3" value="-8.2" spread="12.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Weeks 12 and 24 in Erythrocyte Sedimentation Rate (ESR)</title>
        <description>ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.</description>
        <time_frame>Baseline, Weeks 12 and 24</time_frame>
        <population>All randomized participants who received study drug in Parts A and B and had ESR evaluated at analysis time points.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Weeks 12 and 24 in Erythrocyte Sedimentation Rate (ESR)</title>
          <description>ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.</description>
          <population>All randomized participants who received study drug in Parts A and B and had ESR evaluated at analysis time points.</population>
          <units>mm/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=44, 51, 50, 49, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.6" spread="14.45"/>
                    <measurement group_id="O2" value="-6.4" spread="16.81"/>
                    <measurement group_id="O3" value="-11.5" spread="17.28"/>
                    <measurement group_id="O4" value="-13.9" spread="22.42"/>
                    <measurement group_id="O5" value="-6.0" spread="19.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=0, 50, 48, 45, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore mean and SD were not calculated.</measurement>
                    <measurement group_id="O2" value="-6.9" spread="13.89"/>
                    <measurement group_id="O3" value="-9.2" spread="19.00"/>
                    <measurement group_id="O4" value="-13.7" spread="21.62"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore mean and SD were not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.458</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Weeks 76 and 128 in ESR</title>
        <description>ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.</description>
        <time_frame>Baseline, Weeks 76 and 128</time_frame>
        <population>All participants who received study drug in Parts C and D and had ESR evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg LY3009104 QD - Parts C and D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C. During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.
Dose escalation criteria: ≥6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received 8 mg LY3009104 QD in Parts A, B and C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Weeks 76 and 128 in ESR</title>
          <description>ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.</description>
          <population>All participants who received study drug in Parts C and D and had ESR evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
          <units>mm/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 76 (n=108, 61, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.0" spread="18.84"/>
                    <measurement group_id="O2" value="-7.4" spread="26.28"/>
                    <measurement group_id="O3" value="-8.9" spread="23.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.0" spread="18.74"/>
                    <measurement group_id="O2" value="-8.5" spread="23.11"/>
                    <measurement group_id="O3" value="-15.5" spread="23.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Weeks 12 and 24 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain</title>
        <description>Physician's and Patient's Assessments of Disease Activity (DA) assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeters (mm), where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis was also assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain).</description>
        <time_frame>Baseline, Weeks 12 and 24</time_frame>
        <population>All randomized participants who received study drug in Parts A and B and had physician's and participant’s assessments of disease activity and participant’s pain evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Weeks 12 and 24 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain</title>
          <description>Physician's and Patient's Assessments of Disease Activity (DA) assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeters (mm), where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis was also assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain).</description>
          <population>All randomized participants who received study drug in Parts A and B and had physician's and participant’s assessments of disease activity and participant’s pain evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physician's Assessment of DA - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.9" spread="18.49"/>
                    <measurement group_id="O2" value="-25.0" spread="20.81"/>
                    <measurement group_id="O3" value="-30.4" spread="18.75"/>
                    <measurement group_id="O4" value="-33.5" spread="19.49"/>
                    <measurement group_id="O5" value="-19.0" spread="21.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician's Assessment of DA - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore mean and SD were not calculated.</measurement>
                    <measurement group_id="O2" value="-27.8" spread="21.13"/>
                    <measurement group_id="O3" value="-35.5" spread="17.72"/>
                    <measurement group_id="O4" value="-37.8" spread="18.73"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore mean and SD were not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's Assessment of DA - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.9" spread="27.26"/>
                    <measurement group_id="O2" value="-16.2" spread="22.43"/>
                    <measurement group_id="O3" value="-25.4" spread="21.61"/>
                    <measurement group_id="O4" value="-29.8" spread="21.20"/>
                    <measurement group_id="O5" value="-10.3" spread="22.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's Assessment of DA - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore mean and SD were not calculated.</measurement>
                    <measurement group_id="O2" value="-16.9" spread="24.96"/>
                    <measurement group_id="O3" value="-30.2" spread="21.85"/>
                    <measurement group_id="O4" value="-30.0" spread="20.90"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore mean and SD were not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's Assessment of Pain - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.8" spread="27.39"/>
                    <measurement group_id="O2" value="-14.2" spread="17.82"/>
                    <measurement group_id="O3" value="-25.0" spread="19.22"/>
                    <measurement group_id="O4" value="-25.3" spread="20.31"/>
                    <measurement group_id="O5" value="-8.8" spread="22.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's Assessment of Pain - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore mean and SD were not calculated.</measurement>
                    <measurement group_id="O2" value="-14.7" spread="20.57"/>
                    <measurement group_id="O3" value="-27.3" spread="22.11"/>
                    <measurement group_id="O4" value="-26.9" spread="19.22"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore mean and SD were not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.217</p_value>
            <p_value_desc>P-value is for Physician's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.092</p_value>
            <p_value_desc>P-value is for Physician's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Physician's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Physician's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Patient's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.072</p_value>
            <p_value_desc>P-value is for Patient's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Patient's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Patient's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Patient's Assessment of Pain - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.082</p_value>
            <p_value_desc>P-value is for Patient's Assessment of Pain - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Patient's Assessment of Pain - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Patient's Assessment of Pain - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Weeks 76 and 128 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain</title>
        <description>Physician's and Patient's assessments of DA assessed using a VAS that ranged from 0 to 100 mm, where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain).</description>
        <time_frame>Baseline, Weeks 76 and 128</time_frame>
        <population>All participants who received study drug in Parts C and D and had physician's and participant’s assessments of disease activity and pain evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg LY3009104 QD - Parts C and D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C. During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.
Dose escalation criteria: ≥6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received 8 mg LY3009104 QD in Parts A, B and C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Weeks 76 and 128 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain</title>
          <description>Physician's and Patient's assessments of DA assessed using a VAS that ranged from 0 to 100 mm, where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain).</description>
          <population>All participants who received study drug in Parts C and D and had physician's and participant’s assessments of disease activity and pain evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physician Assessment of DA-Week 76 (n=108, 61, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.3" spread="19.15"/>
                    <measurement group_id="O2" value="-32.3" spread="23.37"/>
                    <measurement group_id="O3" value="-40.5" spread="21.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician Assessment of DA-Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.5" spread="20.32"/>
                    <measurement group_id="O2" value="-31.0" spread="25.54"/>
                    <measurement group_id="O3" value="-34.0" spread="27.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient Assessment of DA-Week 76 (n=108, 61, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.5" spread="26.49"/>
                    <measurement group_id="O2" value="-27.5" spread="25.52"/>
                    <measurement group_id="O3" value="-27.6" spread="24.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient Assessment of DA-Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.9" spread="27.40"/>
                    <measurement group_id="O2" value="-19.3" spread="29.72"/>
                    <measurement group_id="O3" value="-27.6" spread="25.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient Assessment of Pain-Week 76 (n=108, 61, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.1" spread="24.10"/>
                    <measurement group_id="O2" value="-27.3" spread="24.24"/>
                    <measurement group_id="O3" value="-23.4" spread="23.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient Assessment of Pain-Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.2" spread="24.35"/>
                    <measurement group_id="O2" value="-18.0" spread="28.85"/>
                    <measurement group_id="O3" value="-22.3" spread="22.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Weeks 12 and 24 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)</title>
        <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, and remission was DAS28-CRP &lt;2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.</description>
        <time_frame>Baseline, Weeks 12 and 24</time_frame>
        <population>All randomized participants who received study drug in Parts A and B and had DAS28-CRP evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Weeks 12 and 24 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)</title>
          <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, and remission was DAS28-CRP &lt;2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.</description>
          <population>All randomized participants who received study drug in Parts A and B and had DAS28-CRP evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="1.299"/>
                    <measurement group_id="O2" value="-1.40" spread="1.210"/>
                    <measurement group_id="O3" value="-2.09" spread="1.220"/>
                    <measurement group_id="O4" value="-2.15" spread="1.273"/>
                    <measurement group_id="O5" value="-0.98" spread="1.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore mean and SD were not calculated.</measurement>
                    <measurement group_id="O2" value="-1.53" spread="1.187"/>
                    <measurement group_id="O3" value="-2.25" spread="1.054"/>
                    <measurement group_id="O4" value="-2.47" spread="1.280"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore mean and SD were not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Weeks 76 and 128 in DAS28-CRP</title>
        <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using visual analog scale (VAS) (patient's global VAS). DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP &lt;2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.</description>
        <time_frame>Baseline, Weeks 76 and 128</time_frame>
        <population>All participants who received study drug in Parts C and D and had DAS28-CRP evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg LY3009104 QD - Parts C and D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C. During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.
Dose escalation criteria: ≥6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received 8 mg LY3009104 QD in Parts A, B and C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Weeks 76 and 128 in DAS28-CRP</title>
          <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using visual analog scale (VAS) (patient's global VAS). DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP &lt;2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.</description>
          <population>All participants who received study drug in Parts C and D and had DAS28-CRP evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 76 (n=107, 61, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.47" spread="1.23"/>
                    <measurement group_id="O2" value="-2.16" spread="1.28"/>
                    <measurement group_id="O3" value="-2.68" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.56" spread="1.16"/>
                    <measurement group_id="O2" value="-2.02" spread="1.23"/>
                    <measurement group_id="O3" value="-2.35" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders According to European League Against Rheumatism Responder Index Based on 28-joint Count (EULAR28) Baseline Through Weeks 12 and 24</title>
        <description>EULAR28 categorizes clinical response based upon improvement since baseline in DAS modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: TJC28, SJC28, CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score &gt;5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by &gt;0.6 units but ≤1.2 units or post-baseline DAS28 score &gt;3.2 with improvement by &gt;1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by &gt;1.2 units).</description>
        <time_frame>Baseline through Weeks 12 and 24</time_frame>
        <population>All randomized participants who received study drug in Parts A and B and had EULAR28 evaluated at analysis time points.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders According to European League Against Rheumatism Responder Index Based on 28-joint Count (EULAR28) Baseline Through Weeks 12 and 24</title>
          <description>EULAR28 categorizes clinical response based upon improvement since baseline in DAS modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: TJC28, SJC28, CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score &gt;5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by &gt;0.6 units but ≤1.2 units or post-baseline DAS28 score &gt;3.2 with improvement by &gt;1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by &gt;1.2 units).</description>
          <population>All randomized participants who received study drug in Parts A and B and had EULAR28 evaluated at analysis time points.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good Response - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.</measurement>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.</measurement>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.</measurement>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.120</p_value>
            <p_value_desc>P-value is for comparison of the superiority of the LY3009104 dose level vs. placebo for the ordinal levels of response - Week 12. A priori p-value significance threshold: 1-sided ≤0.10.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>P-value is for comparison of the superiority of the LY3009104 dose level vs. placebo for the ordinal levels of response - Week 12. A priori p-value significance threshold: 1-sided ≤0.10.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for comparison of the superiority of the LY3009104 dose level vs. placebo for the ordinal levels of response - Week 12. A priori p-value significance threshold: 1-sided ≤0.10.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for comparison of the superiority of the LY3009104 dose level vs. placebo for the ordinal levels of response - Week 12. A priori p-value significance threshold: 1-sided ≤0.10.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders According to EULAR28 Baseline Through Weeks 76 and 128</title>
        <description>EULAR28 categorizes clinical response based upon improvement since baseline in Disease Activity Score modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score &gt;5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by &gt;0.6 units but ≤1.2 units or post-baseline DAS28 score &gt;3.2 with improvement by &gt;1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by &gt;1.2 units).</description>
        <time_frame>Baseline, Weeks 76 and 128</time_frame>
        <population>All participants who received study drug in Parts C and D and had EULAR28 evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg LY3009104 QD - Parts C and D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C. During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.
Dose escalation criteria: ≥ 6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received 8 mg LY3009104 QD in Parts A, B and C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders According to EULAR28 Baseline Through Weeks 76 and 128</title>
          <description>EULAR28 categorizes clinical response based upon improvement since baseline in Disease Activity Score modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score &gt;5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by &gt;0.6 units but ≤1.2 units or post-baseline DAS28 score &gt;3.2 with improvement by &gt;1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by &gt;1.2 units).</description>
          <population>All participants who received study drug in Parts C and D and had EULAR28 evaluated at analysis time points. LOCF was used to impute missing post-baseline values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good Response - Week 76 (n=107, 61, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response - Week 76 (n=107, 61, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response - Week 76 (n=107, 61, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response - Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response - Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response - Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 12 and 24</title>
        <description>Disease Activity Score (DAS) modified to include 28-joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP [milligrams per liter (mg/L)], and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores &lt;2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders.</description>
        <time_frame>Baseline through Weeks 12 and 24</time_frame>
        <population>All randomized participants who received study drug in Parts A and B and had DAS28-CRP evaluated at analysis time points.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 12 and 24</title>
          <description>Disease Activity Score (DAS) modified to include 28-joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP [milligrams per liter (mg/L)], and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores &lt;2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders.</description>
          <population>All randomized participants who received study drug in Parts A and B and had DAS28-CRP evaluated at analysis time points.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Disease Activity - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.</measurement>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.</measurement>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="NA">Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.409</p_value>
            <p_value_desc>P-value is for Low Disease Activity - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.371</p_value>
            <p_value_desc>P-value is for Low Disease Activity - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Low Disease Activity - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>P-value is for Low Disease Activity - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <p_value_desc>P-value is for Remission - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>P-value is for Remission - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Remission - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P-value is for Remission - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 76 and 128</title>
        <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores &lt;2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders.</description>
        <time_frame>Baseline through Weeks 76 and 128</time_frame>
        <population>All participants who received study drug in Parts C and D and had DAS28-CRP evaluated at analysis time points.</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg LY3009104 QD - Parts C and D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.
Received 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.
Received 4 mg LY3009104 QD in Part C. During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.
Dose escalation criteria: ≥6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D</title>
            <description>Received 8 mg LY3009104 QD in Parts A, B and C.
Received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 76 and 128</title>
          <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores &lt;2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders.</description>
          <population>All participants who received study drug in Parts C and D and had DAS28-CRP evaluated at analysis time points.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Disease activity - Week 76 (n=108, 61, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Week 76 (n=108, 61, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease activity - Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission - Week 128 (n=79, 47, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Through Week 12 in Duration (Minutes) of Morning Stiffness</title>
        <description>The Investigator asked participants about the duration of their morning stiffness (in minutes) in and around the joints and recorded the duration. The Investigator asked the participants about duration of morning stiffness on the day prior to the study visit to capture actual symptoms. If morning stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses.</description>
        <time_frame>Baseline, Weeks 4, 8, 12</time_frame>
        <population>All randomized participants who received study drug in Part A and had morning stiffness evaluated at analysis time points. LOCF was used to impute missing post-baseline values for Week 12 analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline Through Week 12 in Duration (Minutes) of Morning Stiffness</title>
          <description>The Investigator asked participants about the duration of their morning stiffness (in minutes) in and around the joints and recorded the duration. The Investigator asked the participants about duration of morning stiffness on the day prior to the study visit to capture actual symptoms. If morning stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses.</description>
          <population>All randomized participants who received study drug in Part A and had morning stiffness evaluated at analysis time points. LOCF was used to impute missing post-baseline values for Week 12 analysis.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=47, 50, 50, 50, 94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.1" spread="70.49"/>
                    <measurement group_id="O2" value="-27.0" spread="46.49"/>
                    <measurement group_id="O3" value="-57.4" spread="149.00"/>
                    <measurement group_id="O4" value="-25.5" spread="126.13"/>
                    <measurement group_id="O5" value="-22.5" spread="63.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=46, 50, 50, 50, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.2" spread="85.45"/>
                    <measurement group_id="O2" value="-31.1" spread="45.80"/>
                    <measurement group_id="O3" value="-67.8" spread="138.02"/>
                    <measurement group_id="O4" value="-53.8" spread="101.76"/>
                    <measurement group_id="O5" value="-25.5" spread="67.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=48, 51, 50, 50, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.5" spread="72.80"/>
                    <measurement group_id="O2" value="-30.7" spread="47.41"/>
                    <measurement group_id="O3" value="-75.0" spread="142.04"/>
                    <measurement group_id="O4" value="-62.7" spread="88.27"/>
                    <measurement group_id="O5" value="-33.9" spread="91.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.073</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 12 in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores</title>
        <description>The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains (physical functioning, bodily pain, role limitations due to physical problems and also emotional problems, general health, mental health, social functioning and vitality) and 2 component scores (PCS and MCS). The PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. The MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. Both PCS and MCS range from 0-100 with higher scores indicating better health or functioning.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received study drug in Part A and had SF-36 evaluated at analysis time point. LOCF was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 12 in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores</title>
          <description>The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains (physical functioning, bodily pain, role limitations due to physical problems and also emotional problems, general health, mental health, social functioning and vitality) and 2 component scores (PCS and MCS). The PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. The MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. Both PCS and MCS range from 0-100 with higher scores indicating better health or functioning.</description>
          <population>All randomized participants who received study drug in Part A and had SF-36 evaluated at analysis time point. LOCF was used to impute missing post-baseline values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.66" spread="8.074"/>
                    <measurement group_id="O2" value="4.15" spread="7.680"/>
                    <measurement group_id="O3" value="7.07" spread="7.378"/>
                    <measurement group_id="O4" value="7.00" spread="9.054"/>
                    <measurement group_id="O5" value="3.22" spread="6.733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" spread="11.983"/>
                    <measurement group_id="O2" value="1.89" spread="6.869"/>
                    <measurement group_id="O3" value="2.39" spread="7.898"/>
                    <measurement group_id="O4" value="3.03" spread="10.675"/>
                    <measurement group_id="O5" value="0.88" spread="10.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>P-value is for PCS. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.194</p_value>
            <p_value_desc>P-value is for PCS. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for PCS. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>P-value is for PCS. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.449</p_value>
            <p_value_desc>P-value is for MCS. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.578</p_value>
            <p_value_desc>P-value is for MCS. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.140</p_value>
            <p_value_desc>P-value is for MCS. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.266</p_value>
            <p_value_desc>P-value is for MCS. A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 12 in Brief Pain Inventory Modified Short Form (BPI-sf Modified) Worst-Pain-in-the Past-24-hours Item Score</title>
        <description>The BPI-sf modified is a self-administered questionnaire developed for the rapid assessment of pain. The BPI-sf modified provides information on the intensity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The questionnaire asks questions about pain relief, pain quality, and the participant's perception of the cause of pain. The BPI-sf modified uses a numeric rating scale from 0 (“No pain”) to 10 (“Pain as bad as you can imagine”). Since pain can be quite variable over a day, the BPI-sf modified asked participants to rate their pain at the time of responding to the questionnaire (right now), and also at its worst, least and average over the last 24 hours.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received study drug and had BPI-sf worst-pain-in-the past-24-hours item evaluated at Week 12. LOCF was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 12 in Brief Pain Inventory Modified Short Form (BPI-sf Modified) Worst-Pain-in-the Past-24-hours Item Score</title>
          <description>The BPI-sf modified is a self-administered questionnaire developed for the rapid assessment of pain. The BPI-sf modified provides information on the intensity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The questionnaire asks questions about pain relief, pain quality, and the participant's perception of the cause of pain. The BPI-sf modified uses a numeric rating scale from 0 (“No pain”) to 10 (“Pain as bad as you can imagine”). Since pain can be quite variable over a day, the BPI-sf modified asked participants to rate their pain at the time of responding to the questionnaire (right now), and also at its worst, least and average over the last 24 hours.</description>
          <population>All randomized participants who received study drug and had BPI-sf worst-pain-in-the past-24-hours item evaluated at Week 12. LOCF was used to impute missing post-baseline values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="2.547"/>
                    <measurement group_id="O2" value="-0.67" spread="2.132"/>
                    <measurement group_id="O3" value="-1.41" spread="1.813"/>
                    <measurement group_id="O4" value="-1.54" spread="2.131"/>
                    <measurement group_id="O5" value="-0.35" spread="2.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <method_desc>A priori p-value significance threshold: 2-sided ≤0.10.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.135</p_value>
            <p_value_desc>A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 12 in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Score</title>
        <description>The FACIT-F Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 (“Not at all”) to 4 (“Very much”) for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received study drug in Part A and had FACIT-F evaluated at Week 12. LOCF was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 12 in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Score</title>
          <description>The FACIT-F Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 (“Not at all”) to 4 (“Very much”) for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.</description>
          <population>All randomized participants who received study drug in Part A and had FACIT-F evaluated at Week 12. LOCF was used to impute missing post-baseline values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" spread="10.492"/>
                    <measurement group_id="O2" value="3.80" spread="9.152"/>
                    <measurement group_id="O3" value="4.41" spread="8.631"/>
                    <measurement group_id="O4" value="4.11" spread="9.971"/>
                    <measurement group_id="O5" value="2.02" spread="8.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.203</p_value>
            <p_value_desc>A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.164</p_value>
            <p_value_desc>A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.097</p_value>
            <p_value_desc>A priori p-value significance threshold: 2-sided ≤0.10.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104</title>
        <time_frame>Baseline through 24 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of LY3009104 with evaluable LY3009104 PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A. MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
Participants who received Placebo or 1 mg LY3009104 in Part A were re-randomized at Week 12 to receive 2 mg LY3009104 BID in Part B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
Participants who received Placebo or 1 mg LY3009104 in Part A were re-randomized at Week 12 to receive 4 mg LY3009104 QD in Part B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B. MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Population Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104</title>
          <population>All randomized participants who received at least 1 dose of LY3009104 with evaluable LY3009104 PK data.</population>
          <units>nanomoles/Liter (nmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="36.1"/>
                    <measurement group_id="O2" value="59.1" spread="21.3"/>
                    <measurement group_id="O3" value="119.0" spread="20.5"/>
                    <measurement group_id="O4" value="241.0" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population PK: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104</title>
        <time_frame>Baseline through 24 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of LY3009104 with evaluable LY3009104 PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>1mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A. MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
Participants who received Placebo or 1 mg LY3009104 in Part A were re-randomized at Week 12 to receive 2 mg LY3009104 BID in Part B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.
Participants who received Placebo or 1 mg LY3009104 in Part A were re-randomized at Week 12 to receive 4 mg LY3009104 QD in Part B.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B. MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Population PK: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104</title>
          <population>All randomized participants who received at least 1 dose of LY3009104 with evaluable LY3009104 PK data.</population>
          <units>nanomoles*hour/Liter (nmol*h/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333" spread="61.7"/>
                    <measurement group_id="O2" value="541" spread="38.0"/>
                    <measurement group_id="O3" value="1060" spread="37.0"/>
                    <measurement group_id="O4" value="2190" spread="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Through Week 12 in the ENSEMBLE Minimum Data Set 1.0</title>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Zero participants were analyzed. Assessment of ENSEMBLE Minimum Data Set 1.0 was not collected at Week 12 and therefore results are not reported for outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mg LY3009104</title>
            <description>1 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O2">
            <title>2 mg LY3009104</title>
            <description>2 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O3">
            <title>4 mg LY3009104</title>
            <description>4 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O4">
            <title>8 mg LY3009104</title>
            <description>8 mg LY3009104 administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline Through Week 12 in the ENSEMBLE Minimum Data Set 1.0</title>
          <population>Zero participants were analyzed. Assessment of ENSEMBLE Minimum Data Set 1.0 was not collected at Week 12 and therefore results are not reported for outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1 mg LY3009104 QD - Part A</title>
          <description>Administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="E2">
          <title>2 mg LY3009104 QD - Part A</title>
          <description>Administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="E3">
          <title>4 mg LY3009104 QD - Part A</title>
          <description>Administered orally QD for 12 weeks in Pat A.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="E4">
          <title>8 mg LY3009104 QD - Part A</title>
          <description>Administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="E5">
          <title>Placebo QD - Part A</title>
          <description>Placebo administered orally QD for 12 weeks in Part A.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="E6">
          <title>2 mg LY3009104 BID Crossover- Part B</title>
          <description>Participants who received Placebo or 1 mg LY3009104 in Part A were re-randomized at Week 12 to receive 2 mg LY3009104 BID in Part B.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="E7">
          <title>4 mg LY3009104 QD Crossover- Part B</title>
          <description>Participants who received Placebo or 1 mg LY3009104 in Part A were re-randomized at Week 12 to receive 4 mg LY3009104 QD in Part B.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="E8">
          <title>2 mg LY3009104 QD - Part B</title>
          <description>Participants who received 2 mg LY3009104 QD in Part A continued to receive 2 mg LY3009104 QD in Part B.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="E9">
          <title>4 mg LY3009104 QD - Part B</title>
          <description>Participants who received 4 mg LY3009104 QD in Part A continued to receive 4 mg LY3009104 QD in Part B.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="E10">
          <title>8 mg LY3009104 QD - Part B</title>
          <description>Participants who received 8 mg LY3009104 QD in Part A continued to receive 8 mg LY3009104 QD in Part B.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="E11">
          <title>4 mg LY3009104 QD - Part C</title>
          <description>Participants who received 2 mg LY3009104 QD or BID in Part B were re-assigned at Week 24 to 4 mg LY3009104 QD in Part C.
Participants who received 4 mg LY3009104 QD in Part B continued to receive 4 mg LY3009104 QD in Part C.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="E12">
          <title>4 to 8 mg LY3009104 QD Pre-Rescue - Part C</title>
          <description>Participants who received 2 mg LY3009104 QD or BID in Part B were re-assigned at Week 24 to 4 mg LY3009104 QD in Part C.
Participants who received 4 mg LY3009104 QD in Part B continued to receive 4 mg LY3009104 QD in Part C.
During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD (rescue treatment) for the rest of the Part C.
MTX was administered orally as background therapy.
Adverse events were collected from Week 24 until predose of 8 mg LY3009104 QD.</description>
        </group>
        <group group_id="E13">
          <title>4 to 8 mg LY3009104 QD Post-Rescue - Part C</title>
          <description>Participants who received 2 mg LY3009104 QD or BID in Part B were re-assigned at Week 24 to 4 mg LY3009104 QD in Part C.
Participants who received 4 mg LY3009104 QD in Part B continued to receive 4 mg LY3009104 QD in Part C.
During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD (rescue treatment) for the rest of the Part C.
MTX was administered orally as background therapy.
Adverse events were collected from predose of 8 mg LY3009104 QD until Week 76.</description>
        </group>
        <group group_id="E14">
          <title>8 mg LY3009104 QD - Part C</title>
          <description>Participants who received 8 mg LY3009104 QD in Part B remained on 8 mg LY3009104 QD in Part C.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="E15">
          <title>4 mg LY3009104 QD - Part D</title>
          <description>Participants who received 4 mg LY3009104 QD in Part C continued to receive 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="E16">
          <title>4 mg LY3009104 QD (4 to 8 mg Rescue)- Part D</title>
          <description>Participants who received 8 mg LY3009104 QD rescue treatment in Part C received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="E17">
          <title>8/4 mg LY3009104 QD - Part D</title>
          <description>Participants who received 8 mg LY3009104 QD in Part C received 4 mg LY3009104 QD in Part D.
MTX was administered orally as background therapy.</description>
        </group>
        <group group_id="E18">
          <title>Follow-Up</title>
          <description>Up to 28 days post the last dose of study drug.
MTX was administered orally as background therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E11" subjects_affected="16" subjects_at_risk="108"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Large intestinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute hepatitis b</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Diastasis recti abdominis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E10" subjects_affected="18" subjects_at_risk="49"/>
                <counts group_id="E11" subjects_affected="35" subjects_at_risk="108"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E13" subjects_affected="25" subjects_at_risk="61"/>
                <counts group_id="E14" subjects_affected="16" subjects_at_risk="32"/>
                <counts group_id="E15" subjects_affected="24" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="13" subjects_at_risk="47"/>
                <counts group_id="E17" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Acquired oesophageal web</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="9" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E14" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E15" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="9" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E17" events="3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E14" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E11" events="10" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E13" events="8" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E16" events="3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E11" events="15" subjects_affected="12" subjects_at_risk="108"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E13" events="6" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E15" events="4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="4" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E15" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E9" events="5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

